logoslogan
home3.jpg

We are a venture capital firm investing in life science companies covering start-ups to later stage companies. Based in Heidelberg, we invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment modalities and pharmaceuticals, next generation enabling technology platforms or innovations in the diagnostics and medical device area. As an independent and focused team we move quickly with short decision timelines. However, once engaged, we offer our portfolio companies the time and the attention they deserve to make them successful.

EMBL Ventures manages two Funds with a total of € 68m capital on behalf of major European private and institutional investors. We prefer a role as lead or co-lead investor in  financing rounds which typically range from € 5m to € 30m. Our total commitment in a single portfolio company can go as high as € 8m.

As with our portfolio companies each Partner at EMBL Ventures strives to build long-lasting personal relationships with Investors in our Funds, such as institutionals, high net-worth individuals and family offices. These relationships are based on EMBL Ventures' core values of open and prompt communication coupled with the ambition to generate maximum return.

ViraTherapeutics raises €3.6 million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus Platform


Funds will be used to progress ViraTherapeutic’s lead product VSV-GP towards clinical proof of concept in patients with solid tumors.


Continue Reading

Opsona Therapeutics Ltd. Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof

23rd February 2015, Dublin, Ireland – Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune, inflammatory diseases and oncology, today announced that the US Patent Office has issued US Patent 8,623,353, which covers an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof.

Continue Reading

ImevaX welcomes KfW to investor syndicate in second closing of Series A financing

ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, especially in H. pylori infections, announced today that KfW has joined the company's 2014 Series A investor syndicate through a second closing of the financing.

Continue Reading